Rocilinostat

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameRocilinostat
Drug Alias NameRicolinostatACY-63ACY-1215
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 6 inhibitors
TargetsHistone deacetylase 6
Therapy Area/IndicationsDiabetic peripheral neuropathyMetastatic breast cancerPeripheral Nervous System Diseases +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAcetylon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBeijing Bencao Ruisheng Medical Technology Co LtdRegenacy Pharmaceuticals Llc +[5] 
Inactive CompaniesColumbia UniversityNational Cancer InstituteCelgene Corp
Active IndicationsDiabetic peripheral neuropathyPeripheral Nervous System DiseasesLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsMetastatic breast cancerFallopian Tube NeoplasmsOvarian Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A